)
Edge20 Mar 2026
Tetra Pak: The Shape of Innovation
The story of Tetra Pak, the Rausing family, and how a paper tetrahedron gave rise to a company that now delivers almost 180 billion packages a year.
ABIVAX
ABIVAX (ABVX) investor relations material
ABIVAX Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary23 Mar, 2026
Executive summary
Completed pivotal fundraising with $700.3M (€597.2M) net proceeds from a U.S. public offering, significantly strengthening the balance sheet.
Cash, cash equivalents, and short-term investments totaled €530.4M as of December 31, 2025, providing a projected cash runway into Q4 2027.
Advanced Phase 3 ABTECT maintenance trial for obefazimod in ulcerative colitis, with no new safety signals reported by DSMB and topline results expected late Q2 2026.
Strengthened leadership with key hires in commercial, regulatory, and research roles to support growth and commercialization plans.
Financial highlights
R&D expenses rose by €31.2M to €177.8M, mainly due to increased clinical trial and supply chain costs, and expansion into Crohn’s disease and new indications.
G&A expenses increased by €34.7M to €67.7M, primarily from higher personnel costs and employer taxes linked to share price appreciation.
Sales and marketing expenses decreased by €0.8M to €5.2M, reflecting lower one-time rebranding costs offset by higher personnel expenses.
Operating loss widened to €246.1M from €173.0M year-over-year; net loss for 2025 was €336.1M compared to €176.2M in 2024.
Settled all outstanding debt tranches and convertible notes, reducing borrowings from €101.0M to €1.9M.
Outlook and guidance
Topline results for the ABTECT-UC Phase 3 maintenance trial expected in late Q2 2026; NDA submission for obefazimod in UC targeted for Q4 2026, pending positive data.
Cash runway projected into Q4 2027 under current operating assumptions.
Q1 2026 financial results to be reported on May 25, 2026.
Detail the path from Q2 data to Q4 NDA filing
Explain the €27.3M social tax from share growth
How will Entyvio experience shape the UC launch?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from ABIVAX
- ABTECT Phase 3 completed enrollment; key data and NDA submission expected by 2026.ABVX
AGM 202523 Mar 2026 - Up to $350M in securities, including $150M ADSs via ATM, to fund R&D and growth initiatives.ABVXRegistration Filing16 Dec 2025
- Cash position strengthened and debt reduced, with net loss rising on higher R&D and non-cash items.ABVXQ3 202515 Dec 2025
- 50mg oral therapy showed strong efficacy and safety in severe, refractory UC across subgroups.ABVXThe United European Gastroenterology (UEG) Congress UEG Week 202514 Dec 2025
- Obefazimod 50 mg achieved significant remission and safety in Phase 3 UC trials.ABVXStudy Result14 Oct 2025
- Positive phase 3 results and a €637.5M ($747.5M) offering extended cash runway to Q4 2027.ABVXQ2 202510 Sep 2025
- Obefazimod's Phase 3 UC trial is on track, with strong efficacy, safety, and market potential.ABVXCorporate Presentation4 Jul 2025
- Net loss widened to €81.6M as R&D spending surged, with cash runway into Q4 2025.ABVXH1 202413 Jun 2025
- Obefazimod shows promise as a differentiated oral IBD therapy with strong clinical and financial momentum.ABVXCorporate Presentation13 Jun 2025
Next ABIVAX earnings date
Q1 202625 May, 2026
ABIVAX
Next ABIVAX earnings date
Q1 202625 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage